Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

Clinical and Prognostic Relevance of Magnetic Resonance Imaging of the Spine in Newly Diagnosed Multiple Myeloma Patients Receiving Autologous Stem Cell Transplantation.

Patrizia Tosi, M.D., Alessandro Petrucci, M.D., Lucia Pantani, M.D., Elena Zamagni, Paola Tacchetti, M.D., Giulia Perrone, M.D., Annamaria Brioli, M.D., Michela Ceccolini, M.D., Michele Baccarani, MD, Michele Cavo, MD

Blood (2009) 114 (22): 4885.

https://doi.org/10.1182/blood.V114.22.4885.4885

Published: 2009

Journal Articles

Thalidomide and Dexamethasone as Salvage Therapy after First Relapse in Multiple Myeloma: Analysis of Long-Term Outcomes.

Elena Zamagni, M.D., Alessandro Petrucci, M.D., Patrizia Tosi, M.D., Paola Tacchetti, M.D., Lucia Pantani, M.D., Annamaria Brioli, M.D., Maria Caterina Pallotti, M.D., Giulia Perrone, M.D., Michele Baccarani, M.D., Michele Cavo, MD

Blood (2009) 114 (22): 4933.

https://doi.org/10.1182/blood.V114.22.4933.4933

Published: 2009

Journal Articles

Thalidomide-Dexamethasone as Induction Therapy Prior to Autologous Stem-Cell Transplantation in Patients with Newly Diagnosed Multiple Myeloma and Renal Failure.

Patrizia Tosi, M.D., Elena Zamagni, Paola Tacchetti, M.D., Michela Ceccolini, M.D., Giulia Perrone, M.D., Annamaria Brioli, M.D., Lucia Pantani, M.D., Alessandro Petrucci, M.D., Michele Baccarani, MD, Michele Cavo, MD

Blood (2009) 114 (22): 4934.

https://doi.org/10.1182/blood.V114.22.4934.4934

Published: 2009

Journal Articles

Incorporation of Thalidomide-Dexamethasone (Thal-Dex) into up-Front Double Autologous Stem-Cell Transplantation (ASCT) for multiple Myeloma: Final analysis of phase II “Bologna 2002” Study.

Blood (2009) 114 (22): 349.

https://doi.org/10.1182/blood.V114.22.349.349

Published: 2009

Journal Articles

Superior Complete Response Rate and Progression-Free Survival after Autologous Transplantation with up-Front Velcade-Thalidomide- Dexamethasone Compared with Thalidomide-Dexamethasone in Newly Diagnosed Multiple Myeloma

Blood (2008) 112 (11): 158.

https://doi.org/10.1182/blood.V112.11.158.158

Published: 2008

Journal Articles

Bortezomib (Velcade®)-Thalidomide-Dexamethasone (VTD) vs Thalidomide-Dexamethasone (TD) in Preparation for Autologous Stem-Cell (SC) Transplantation (ASCT) in Newly Diagnosed Multiple Myeloma (MM).

Blood (2007) 110 (11): 73.

https://doi.org/10.1182/blood.V110.11.73.73

Published: 2007

Journal Articles

Superiority of Double over Single Autologous Stem-Cell Transplantation for Newly Diagnosed Multiple Myeloma and Prognostic Impact of Complete Response: Final Analysis of “Bologna 96” Study.

Michele Cavo, MD, Giulia Perrone, M.D., Michela Ceccolini, M.D., Vito Michele Lauta, M.D., Massimo Offidani, M.D., Filippo Ballerini, M.D., Lucia Pantani, M.D., Annamaria Brioli, M.D., Silvana Pasini, M.D., Fausto Dore, M.D., Domenico Vertone, M.D., Paola Tacchetti, M.D., Elena Zamagni, M.D., Patrizia Tosi, M.D., Sante Tura, M.D., Michele Baccarani, M.D.

Blood (2007) 110 (11): 730.

https://doi.org/10.1182/blood.V110.11.730.730

Published: 2007

NARROW

Clinical and Prognostic Relevance of Magnetic Resonance Imaging of the Spine in Newly Diagnosed Multiple Myeloma Patients Receiving Autologous Stem Cell Transplantation.

Thalidomide and Dexamethasone as Salvage Therapy after First Relapse in Multiple Myeloma: Analysis of Long-Term Outcomes.

Thalidomide-Dexamethasone as Induction Therapy Prior to Autologous Stem-Cell Transplantation in Patients with Newly Diagnosed Multiple Myeloma and Renal Failure.

Incorporation of Thalidomide-Dexamethasone (Thal-Dex) into up-Front Double Autologous Stem-Cell Transplantation (ASCT) for multiple Myeloma: Final analysis of phase II “Bologna 2002” Study.

Superior Complete Response Rate and Progression-Free Survival after Autologous Transplantation with up-Front Velcade-Thalidomide- Dexamethasone Compared with Thalidomide-Dexamethasone in Newly Diagnosed Multiple Myeloma

Bortezomib (Velcade®)-Thalidomide-Dexamethasone (VTD) vs Thalidomide-Dexamethasone (TD) in Preparation for Autologous Stem-Cell (SC) Transplantation (ASCT) in Newly Diagnosed Multiple Myeloma (MM).

Superiority of Double over Single Autologous Stem-Cell Transplantation for Newly Diagnosed Multiple Myeloma and Prognostic Impact of Complete Response: Final Analysis of “Bologna 96” Study.

Email alerts

ASH Publications

American Society of Hematology

Clinical and Prognostic Relevance of Magnetic Resonance Imaging of the Spine in Newly Diagnosed Multiple Myeloma Patients Receiving Autologous Stem Cell Transplantation.

Thalidomide and Dexamethasone as Salvage Therapy after First Relapse in Multiple Myeloma: Analysis of Long-Term Outcomes.

Thalidomide-Dexamethasone as Induction Therapy Prior to Autologous Stem-Cell Transplantation in Patients with Newly Diagnosed Multiple Myeloma and Renal Failure.

Incorporation of Thalidomide-Dexamethasone (Thal-Dex) into up-Front Double Autologous Stem-Cell Transplantation (ASCT) for multiple Myeloma: Final analysis of phase II “Bologna 2002” Study.

Superior Complete Response Rate and Progression-Free Survival after Autologous Transplantation with up-Front Velcade-Thalidomide- Dexamethasone Compared with Thalidomide-Dexamethasone in Newly Diagnosed Multiple Myeloma

Bortezomib (Velcade®)-Thalidomide-Dexamethasone (VTD) vs Thalidomide-Dexamethasone (TD) in Preparation for Autologous Stem-Cell (SC) Transplantation (ASCT) in Newly Diagnosed Multiple Myeloma (MM).

Superiority of Double over Single Autologous Stem-Cell Transplantation for Newly Diagnosed Multiple Myeloma and Prognostic Impact of Complete Response: Final Analysis of “Bologna 96” Study.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only